logo
Shared Decision-Making in Postoperative Pain Management

Shared Decision-Making in Postoperative Pain Management

Medscape24-07-2025
This transcript has been edited for clarity.
Jeff Gadsden, MD: Hello, I'm Dr Jeff Gadsden, a professor of anesthesiology at Duke University Hospital in North Carolina. And with me is Dr Eliana Saltzman, an orthopedic surgeon whom I work with frequently. Welcome, Eliana.
Eliana Saltzman, MD: Thank you so much for having me today. I'm really excited to be here with you.
Gadsden: It's my pleasure.
Today we're going to talk in this Care Cues conversation about having a preoperative discussion with our patients about postoperative pain management in a way that fosters shared decision-making, as well as a reduction in opioid prescriptions.
Saltzman: I am a hand and upper-extremity surgeon, so, high-volume surgery, high number of prescriptions of opioids. For me and my practice, this is a really important topic, especially as we meet patients and discuss where we go next in terms of expectations at the peri-op period.
Gadsden: Absolutely.
Partnering Against Pain
Gadsden: So, let's think about this in terms of the way that I think about surgery: There's a preoperative phase, an intraoperative phase, and a postoperative phase.
In the preoperative phase, how important is it to get with your patient and have that discussion and set expectations about what their pain management is going to look like afterwards?
Saltzman: I think it's a huge part of it: setting expectations for the patients and explaining what their postoperative course is going to look like, as well as briefing them on their intraoperative anesthetic options that they have available.
There has been a lot of research that has shown that the preoperative discussion — in terms of multimodal analgesic options — has huge ramifications in terms of the decreased number of opioid prescriptions actually taken but also patients reporting better pain scores as well.
Precision Pain Management
Gadsden: Let's get down to nuts and bolts here.
So, if I'm coming through your clinic and I'm going to get an elbow operation, what multimodal agents are you likely to prescribe for me before I even get to the OR?
Saltzman: I will ask you to take acetaminophen and ibuprofen. Alternate between the two medications and take one of those medications every 4 hours.
And I like that more than taking the same quantity of each once or twice a day, because that way you can really have something always on board every 4 hours. And, again, trying to prepare patients for that post-op period, I really try not to prescribe any opioid pre-op so that postoperatively it is as efficacious as possible.
Gadsden: Yeah, I love that. That's my magic recipe too. The acetaminophen, NSAID (nonsteroidal anti-inflammatory drug), acetaminophen, NSAID, every 3 or 4 hours, and I present that to friends and family when they have aches and pains.
Saltzman: Me too.
I think in this new era, there's a tremendous focus on the multimodal, that ibuprofen and acetaminophen should be taken routinely for the first 3-5 days after surgery and that the role of opioids should really be for breakthrough pain.
Gadsden: In the old days, we used to rely on them as our first and sometimes monotherapy, right? Have you seen a reduction in the number of patients that need any opioids?
Saltzman: For soft tissue only, small hand procedures — I like to call them procedures and not surgeries to create the mindset of this being a very small operation — there has been quite a bit of research in hand and upper extremity surgery to understand that if you are going to prescribe an opioid, how many do you need to prescribe?
Because it's not the same for every patient. On the basis of age, length of procedure time, whether it's soft tissue or bony, that number should really be different. Rather than in the old days when everybody got a huge number of opioids no matter what the procedure was.
Gadsden: Yeah. I used to see 90 pills going home with patients every day.
Saltzman: 120 for a total knee replacement was not uncommon.
Gadsden: Right. So, what I hear you saying is that we're moving towards an era of more precision pain management where you tell patients, 'Alright, you're getting this operation, so I'm going to give you my usual multimodal regimen plus six oxy.'
Saltzman: Even five. Or none. I mean, I have a lot of patients say, 'I really don't want any,' and I think that's absolutely fine.
Sometimes I'll still send it to the pharmacy so it's there for them. So, we've really swung in the other direction, which is great, but sometimes it can leave patients in that acute post-op period without any coverage.
Staying Ahead of Pain
There's this whole concept around being behind pain or chasing your pain. How do you manage that? Or what does that conversation look like for you?
Gadsden: When I trained back in the 1900s, the common wisdom was: get pain, take some opioid, take some more opioid, take some more opioid. And of course, that wisdom has led us down the path to where we are today with the opioid crisis. And so, the idea of never letting someone have pain is a little bit obsolete.
I think we've tweaked that a bit with a focus on the multimodal. So, to your point earlier — if you take acetaminophen, NSAID, acetaminophen, NSAID — that's a good thing to stress getting in there early and really making sure that you never miss those doses rather than saying you have to take opioids and never have pain.
Expanding the Toolbox
Saltzman: Are there any other novel therapies that you think are coming about or other ways that we can help control our peri-op, post-op pain?
Gadsden: There are some new things coming down the pike that are showing a lot of promise. A drug that comes to mind is one called suzetrigine, which is a pill you can take for a week or two after surgery. It works on the same sodium channels that we would target with a nerve block. But instead of getting a numb hand and a hand you can't move, it only targets the pain fibers. And so, you can move your hand and you can feel your hand, but you don't have pain or you have less pain. So that's exciting.
Saltzman: And that's just for acute pain or patients who also have chronic pain?
Gadsden: Both acute and chronic pain for that type of drug. And then another exciting one that we're using now currently at Duke is cryotherapy. So, the idea is you take a device and with ultrasound guidance, put the tip of a needle next to a nerve, press a button, and an ice ball forms near the nerve and in effect deactivates it. The nerve grows back over time, but it takes weeks and weeks and weeks and sometimes people get pain relief for months out after cryotherapy.
In Patients' Hands
Saltzman: So now we have all these amazing new modalities and this multimodal pain regimen. How has that translated as we've moved more and more patients to become postoperative outpatients, either going home the same day or being in-patients for much shorter hospitalizations?
Gadsden: When I was in residency, you did a total knee replacement on someone and they would stay in the hospital for 5 days. Giving someone an opioid in a hospital setting is in many ways a much safer proposition than if you send someone home with the same opioid. The switch to a much more ambulatory style of practice has put different challenges and stresses on our decision making.
And certainly, it fits in nicely with that idea of giving a voice to the patient. Asking them: You're going to be at home, you're not going to have a nurse knocking on your door every 4 hours. How do you see us managing your pain in a way that works best for you, your schedule, your home, and that sort of thing?
Giving Patients the Choice
Gadsden: I'm interested in the concept of shared decision-making, but have you heard of cases where the shared decision-making wasn't quite so great and there was a downstream consequence?
Saltzman: There are patients who I've met who are really unhappy with prior surgeons who say, 'No one even gave me a choice. I didn't even know I could have it just with a block or just with local. Like I would have picked this.'
Sometimes patients can't make that decision in the clinic, which is fine. And getting to go home, think about it, read more about the various options, and then come the day of surgery saying, 'Okay, I've made up my mind.' Or, 'I'd really like to talk to the anesthesiologist a little bit more about these different options and what my postoperative course might look like.' And I think letting them decide always leads to happier patients who feel like they have more control of their postoperative course.
Gadsden: There's no question in my mind that giving patients agency and making them feel like, "I have a stake in this. I've got skin in the game now. I want to know all the facts, what my options are, and make a decision," helps with their satisfaction afterwards.
Saltzman: Yep.
Gadsden: Well, Dr Saltzman, as always, it has been a huge pleasure to talk to you about this topic that we're so passionate about: keeping people safe and keeping people comfortable.
Saltzman: Thank you again for inviting me today. It was great chatting with you.
Gadsden: Likewise.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Novel Tool May Predict NSAID Hypersensitivity
Novel Tool May Predict NSAID Hypersensitivity

Medscape

time2 days ago

  • Medscape

Novel Tool May Predict NSAID Hypersensitivity

TOPLINE: A new risk stratification tool known as CA4TCH — which relies solely on clinical history — could help predict which patients with a suspected hypersensitivity to nonsteroidal anti-inflammatory drugs (NSAIDs) will have a hypersensitivity confirmed during a drug provocation test. METHODOLOGY: To develop and validate CA4TCH, researchers conducted a retrospective study of 1035 patients who presented with suspected NSAID hypersensitivity at the allergy unit of the University Hospital of Montpellier in Montpellier, France, between February 2001 and December 2020 and underwent drug provocation testing. Using elements of the clinical history — including sex; age at the last reaction; reaction onset ≤ 24 hours; whether the last reaction occurred in the past 5 years; history of anaphylaxis or respiratory symptoms; reactions to two or more drug classes; reaction to aspirin; and comorbid atopy, asthma, sinus disease, or chronic spontaneous urticaria — the team constructed a risk score to predict the presence of a drug hypersensitivity reaction. They then validated the risk score in an independent cohort of 69 participants from the University Hospital of Tours, Tours, France. TAKEAWAY: Overall, 232 (22.4%) participants had at least one positive result during drug provocation testing, whereas 803 (77.6%) did not react to the suspected culprit NSAIDs. The CA4TCH tool had a sensitivity of 78.4%, specificity of 70.4%, and positive and negative predictive values of 43.3% and 91.9%, respectively. Among participants with a negative result, the model successfully delabeled 565 of 803 cases (70.4%). In these cases, past symptoms commonly included angioedema, urticaria, or pruritus. External validation showed comparable predictive performance. IN PRACTICE: 'Given existing variation in testing protocols across clinical centers, the fact that the CA4TCH score is based on clinical history elements alone means it can be used to generate a prediction for any individual upon presentation and could thus constitute a practical tool to be used alongside or as part of existing phenotype classifications,' the authors of the study wrote. SOURCE: Ileana-Maria Ghiordanescu, MD, PhD, with the Carol Davila University of Medicine and Pharmacy, Bucharest, Romania, was the corresponding author of the study, which was published online on July 16 in The Journal of Allergy and Clinical Immunology: In Practice. LIMITATIONS: Fixed drug eruptions were underrepresented in the study, and the researchers did not consider food allergy phenotypes because they lacked information about food sensitization. DISCLOSURES: Some authors reported receiving financial support, including grants, consulting fees, honoraria, or support for attending meetings, from institutions and pharmaceutical companies. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Veterinary Referral Center of Central Oregon Expands Life-Saving Treatment Options With Extracorporeal Therapies
Veterinary Referral Center of Central Oregon Expands Life-Saving Treatment Options With Extracorporeal Therapies

Miami Herald

time2 days ago

  • Miami Herald

Veterinary Referral Center of Central Oregon Expands Life-Saving Treatment Options With Extracorporeal Therapies

Now Offering Veterinary Hemodialysis, Therapeutic Plasma Exchange, and Hemoperfusion BEND, OR / ACCESS Newswire / August 12, 2025 / The Veterinary Referral Center of Central Oregon (VRCCO) is proud to announce the addition of advanced Extracorporeal Therapies, including Hemodialysis, Therapeutic Plasma Exchange, and Hemoperfusion, to its suite of specialized veterinary services. VRCCO is honored to be among the few facilities in the US to offer these cutting-edge treatments that provide new hope for pets suffering from acute kidney injuries, chronic kidney disease, immune-mediated diseases, and life-threatening toxicities. Hemodialysis serves as an "artificial kidney" by filtering a pet's blood to remove harmful substances such as waste, toxins, and excess fluids. While it does not directly heal the kidneys, it provides a vital window of time for recovery, while significantly improving comfort and quality of life for the pet during this critical period. Hemodialysis is most commonly used for acute kidney injuries, severe electrolyte imbalances, fluid overload, and certain toxicities. Therapeutic Plasma Exchange (TPE) is a procedure designed to remove harmful substances from a pet's plasma, replacing it with donor plasma. This therapy is particularly effective in managing severe immune-mediated conditions such as immune-mediated hemolytic anemia (IMHA) and myasthenia gravis, as well as certain toxicities. Pets may experience rapid improvement, particularly with immune-mediated diseases that are unresponsive to conventional treatments. Hemoperfusion involves filtering a pet's blood through a cartridge containing activated charcoal or similar materials to adsorb toxins. This technique is especially valuable in cases of NSAID overdoses (e.g., ibuprofen, carprofen) or exposure to other harmful substances where no antidote exists. Treatments are generally completed within 2-4 hours, and a single session is often sufficient if administered before organ damage occurs. VRCCO utilizes the same advanced dialysis machines and materials used in human medicine, ensuring the highest standards of care. Throughout treatments, patients are continuously monitored for vital parameters including blood clotting times, fluid balance, hematocrit, electrolytes, and cardiac health, with personalized attention from their care team. Pet Parents should also be aware of the following while considering these therapies: Comfort & Compassionate Care: Dialysis treatments are not painful. Pets rest comfortably on soft bedding under the continuous care and observation of VRCCO's specialized team. Sedation is rarely Size & Suitability: Most companion animals, regardless of size, can be safely treated. VRCCO's in-house blood bank ensures the availability of transfusions if & Expectations: Treatment outcomes are highly variable and depend on the severity and cause of the condition. Some pets may require only a few treatments, while others may need ongoing Intervention is Critical: Starting dialysis before severe complications arise, such as fluid overload or organ dysfunction, dramatically improves the likelihood of a positive outcome. The Veterinary Referral Center's board-certified specialists encourage pet parents and referring veterinarians to consult with them to determine whether these therapies are appropriate for individual cases. In many situations, time is a critical factor and early intervention can be life-saving. To learn more about Extracorporeal Therapies or VRCCO's comprehensive specialty services, please contact the Veterinary Referral Center of Central Oregon at 541-209-6960 or info@ Contact Information Katie Sedivec Marketing Directormarketing@ SOURCE: Veterinary Referral Center of Central Oregon press release

Fast Five Quiz: Sjögren Disease Management
Fast Five Quiz: Sjögren Disease Management

Medscape

time25-07-2025

  • Medscape

Fast Five Quiz: Sjögren Disease Management

Learn more about ocular dryness in Sjögren disease. B cells have been shown to significantly impact the pathogenesis of primary Sjögren disease. However, B-cell targeted therapies are generally considered in severe, refractory cases, or in patients with systemic involvement. Specially, the EULAR recommends considering B-Cell targeted therapies only in severe, refractory systemic disease. This is consistent with recommendations from the Sjögren's Foundation, wherein most biologic therapies are recommended for refractory cases or those with systemic involvement. Additionally, the Sjögren's Foundation specifically recommends against the use of tumor necrosis factor inhibitors to treat sicca symptoms in patients with Sjögren disease. Learn more about B-cell therapies for Sjögren disease. Pulmonary manifestations of Sjögren disease, which include interstitial lung disease, are a potentially serious complication of the disease. For patients with symptomatic cystic vocal cord lesions (bamboo nodules), the Sjögren's Foundation recommends voice therapy, inhaled corticosteroids, or intralesional corticosteroid injections. A recent review has further confirmed these approaches are most appropriate in this setting. Nebulized saline is usually recommended for patients with Sjögren disease and ' clinically relevant bronchiectasis.' Systemic corticosteroids are not usually recommended as an initial treatment in this setting; they are typically used for other pulmonary manifestations, such as interstitial lung disease and certain small airway diseases. Surgical resection is typically considered when these approaches fail and after a consultation with a laryngologist. Learn more about pulmonary manifestations in Sjögren disease. For patients with Sjögren disease and acute musculoskeletal pain, EULAR recommends limiting NSAID use to no more than 10 days at full dosage, citing evidence that one third of patients will have a rapid clinical response to short-term analgesics. For inflammatory musculoskeletal pain, the Sjögren's Foundation guidelines recommend hydroxychloroquine and/or methotrexate, progressing to corticosteroids, then leflunomide, sulfasalazine, azathioprine, and cyclosporine. EULAR also suggests hydroxychloroquine for this indication due its effectiveness in other systemic autoimmune diseases but note a pivotal RCT did not show significant benefit. As such, they emphasize nonpharmacologic management of chronic pain and note that treatment should follow general chronic pain guidance. Learn more about pain in Sjögren disease. Editor's Note: This article was created using several editorial tools, including generative AI models, as part of the process. Human review and editing of this content were performed prior to publication. Lead image: Peakstock/Science Source

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store